| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Director/PDMR Shareholding
RNS
|
RNS Number : 0271F
GlaxoSmithKline PLC
11 November 2020
GlaxoSmithKline plc
(the '
Company
')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.6231
|
9 (partnership shares)
|
|
|
|
£14.6231
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mr R Connor
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.6231
|
9 (partnership shares)
|
|
|
|
£14.6231
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Ms D Conrad
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£
14.6231
|
9 (partnership shares)
|
|
|
|
£
14.6231
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mr J Ford
|
|
b)
|
Position/status
|
SVP and General Counsel
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.6231
|
8 (partnership shares)
|
|
|
|
£
14.6231
|
8 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
16 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics and Compliance
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£
14.6231
|
9 (partnership shares)
|
|
|
|
£
14.6231
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Ms S Jackson
|
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£
14.6231
|
9 (partnership shares)
|
|
|
|
£
14.6231
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mr D Jackson
|
|
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£
14.6231
|
9 (partnership shares)
|
|
|
|
£
14.6231
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mr D Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£
14.6231
|
9 (partnership shares)
|
|
|
|
£
14.6231
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mr R Simard
|
|
b)
|
Position/status
|
President, Pharmaceuticals Supply Chain
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£
14.6231
|
9 (partnership shares)
|
|
|
|
£
14.6231
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Mr P Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£
14.6231
|
8 (partnership shares)
|
|
|
|
£
14.6231
|
8 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
16 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Ms D Waterhouse
|
|
b)
|
Position/status
|
Chief Executive Officer of ViiV Healthcare
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£
14.6231
|
9 (partnership shares)
|
|
|
|
£
14.6231
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Ms V Whyte
|
|
b)
|
Position/status
|
Company Secretary
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£
14.6231
|
9 (partnership shares)
|
|
|
|
£
14.6231
|
9 (matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
Aggregated volume Price
|
18 Ordinary Shares
£
14.6231
|
|
e)
|
Date of the transaction
|
2020-11-10
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
DSHEFLFFBFLBFBQ
|
|
|
|
|
|
